198 related articles for article (PubMed ID: 1518837)
21. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
22. The structure of C2b, a fragment of complement component C2 produced during C3 convertase formation.
Krishnan V; Xu Y; Macon K; Volanakis JE; Narayana SV
Acta Crystallogr D Biol Crystallogr; 2009 Mar; 65(Pt 3):266-74. PubMed ID: 19237749
[TBL] [Abstract][Full Text] [Related]
23. The low C5 convertase activity of the C4A6 allotype of human complement component C4.
Kinoshita T; Dodds AW; Law SK; Inoue K
Biochem J; 1989 Aug; 261(3):743-8. PubMed ID: 2803239
[TBL] [Abstract][Full Text] [Related]
24. Amino acid residues 1101-1105 of the isotypic region of human C4B is important to the covalent binding activity of complement component C4.
Reilly BD; Levine RP; Skanes VM
J Immunol; 1991 Nov; 147(9):3018-23. PubMed ID: 1919003
[TBL] [Abstract][Full Text] [Related]
25. Evidence for the involvement of arginine 462 and the flanking sequence of human C4 beta-chain in mediating C5 binding to the C4b subcomponent of the classical complement pathway C5 convertase.
Ebanks RO; Isenman DE
J Immunol; 1995 Mar; 154(6):2808-20. PubMed ID: 7876551
[TBL] [Abstract][Full Text] [Related]
26. Identification of a surface structure in the fourth component of human complement, C4, which becomes hidden upon activation by C1(-)s.
Maeda S; Takamaru Y; Fukatsu J; Nagasawa S
Biochem J; 1993 Jan; 289 ( Pt 2)(Pt 2):503-8. PubMed ID: 7678736
[TBL] [Abstract][Full Text] [Related]
27. Generation of the classical pathway C3 convertase (EAC4b2a) by proteolytic enzymes.
Loos M; Heinz HP
Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():67-74. PubMed ID: 6375257
[TBL] [Abstract][Full Text] [Related]
28. Active sites in complement component C3 mapped by mutations at indels.
Ogata RT; Ai R; Low PJ
J Immunol; 1998 Nov; 161(9):4785-94. PubMed ID: 9794410
[TBL] [Abstract][Full Text] [Related]
29. The effects of iodine and thiol-blocking reagents on complement component C2 and on the assembly of the classical-pathway C3 convertase.
Kerr MA; Parkes C
Biochem J; 1984 Apr; 219(2):391-9. PubMed ID: 6611150
[TBL] [Abstract][Full Text] [Related]
30. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
31. The third component of Xenopus complement: cDNA cloning, structural and functional analysis, and evidence for an alternate C3 transcript.
Lambris JD; Pappas J; Mavroidis M; Wang Y; Manzone H; Schwager J; Du Pasquier L; Silibovsky R; Swager J [corrected to Schwager J]
Eur J Immunol; 1995 Feb; 25(2):572-8. PubMed ID: 7875221
[TBL] [Abstract][Full Text] [Related]
32. Common evolutionary origin of alpha 2-macroglobulin and complement components C3 and C4.
Sottrup-Jensen L; Stepanik TM; Kristensen T; Lønblad PB; Jones CM; Wierzbicki DM; Magnusson S; Domdey H; Wetsel RA; Lundwall A
Proc Natl Acad Sci U S A; 1985 Jan; 82(1):9-13. PubMed ID: 2578664
[TBL] [Abstract][Full Text] [Related]
33. Structural requirements for thioester bond formation in human complement component C3. Reassessment of the role of thioester bond integrity on the conformation of C3.
Isaac L; Isenman DE
J Biol Chem; 1992 May; 267(14):10062-9. PubMed ID: 1577777
[TBL] [Abstract][Full Text] [Related]
34. The C5 convertase is not required for activation of the terminal complement pathway in murine experimental cerebral malaria.
Ramos TN; Darley MM; Weckbach S; Stahel PF; Tomlinson S; Barnum SR
J Biol Chem; 2012 Jul; 287(29):24734-8. PubMed ID: 22689574
[TBL] [Abstract][Full Text] [Related]
35. Human complement component C3: cDNA coding sequence and derived primary structure.
de Bruijn MH; Fey GH
Proc Natl Acad Sci U S A; 1985 Feb; 82(3):708-12. PubMed ID: 2579379
[TBL] [Abstract][Full Text] [Related]
36. Multiple domains of MASP-2, an initiating complement protease, are required for interaction with its substrate C4.
Duncan RC; Bergström F; Coetzer TH; Blom AM; Wijeyewickrema LC; Pike RN
Mol Immunol; 2012 Jan; 49(4):593-600. PubMed ID: 22071314
[TBL] [Abstract][Full Text] [Related]
37. A molecular switch governs the interaction between the human complement protease C1s and its substrate, complement C4.
Perry AJ; Wijeyewickrema LC; Wilmann PG; Gunzburg MJ; D'Andrea L; Irving JA; Pang SS; Duncan RC; Wilce JA; Whisstock JC; Pike RN
J Biol Chem; 2013 May; 288(22):15821-9. PubMed ID: 23592783
[TBL] [Abstract][Full Text] [Related]
38. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
Kozlov LV; Shibanova ED; Zinchenko AA
Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
[TBL] [Abstract][Full Text] [Related]
39. Unique C1 inhibitor dysfunction in a kindred without angioedema. I. A mutant C1 INH that inhibits C1-s but not C1-r.
Wisnieski JJ; Knauss TC; Yike I; Dearborn DG; Narvy RL; Naff GB
J Immunol; 1994 Mar; 152(6):3199-209. PubMed ID: 8144914
[TBL] [Abstract][Full Text] [Related]
40. Autolytic fragmentation of complement components C3 and C4 and its relationship to covalent binding activity.
Sim RB; Sim E
Ann N Y Acad Sci; 1983; 421():259-76. PubMed ID: 6202197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
